Optimizing the workflow for therapeutic viral vectors – upstream and downstream

July 18th 2019, 08:00 PST; 11:00 EST; 16:00 BST; 17:00 CST

As an industry we can make viral vectors. Now it is time to refine processes to achieve the yield and quality needed to support research, development, and commercialization while controlling costs. Collectively, small changes in unit operations can have a big impact on developing a process that is efficient and scalable, yet flexible enough to adapt over time.
  • Understand the key challenges with viral vector production and identify the major bottleneck steps
  • Find out how industry leaders are currently addressing issues with current production volumes and titers, and seeking to alleviate the capacity crunch
  • Get updated on the latest advances with stable producer cell lines and improved purification techniques
  • Gain high-level regulatory insights around viral vector bioprocessing
Lesley Chan
Senior Scientist, Vector Process Development
bluebird bio
View Biography
Spencer Hoover
Director of Process and Analytical Development - Centre for Advanced Therapeutic Cell Technologies
Centre for Commercialization of Regenerative Medicine (CCRM)
View Biography
Francesca Bellintani
Downstream Vector Process Development Manager
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)